
Pharmacovigilance Programme of India (PvPI): Progress and Challenges ahead

Prof. YK Gupta National Scientific Coordinator, PvPI

Facts about safety of Medicines

- The incidence of drug-related admissions range from 0.2 to 22% (WHO Data)
- Nearly 10–20% of acute geriatric hospital admissions are related to ADRs







Indian data need to be generated

WHO Data

 Nearly 7% of medication errors potentially harmful but preventable ADRs





Indian data need to be generated

 Worldwide more than 50% of all medicines are prescribed, dispensed or sold inappropriately



• 50% of patients fail to take them correctly



Increased ADR's

- ↑ Prolongation of Hospital Stay (median 5 days)
- Decreased compliance
- Drug Resistance and Cost Implications (USD 150 per patient)



CAN HE AFFORD AN ADR ???

Patel et al. BMC Clin Pharmacol. 2007 Jul 28;7:8

Scope of Pharmacovigilance

New Drugs and Spontaneous Reporting



- Medication errors and irrational use of medicines
- Herbal, traditional and complimentary medicines
- Substandard medicines and counterfeit medicines
- Blood products, biologicals, medical devices and vaccines

Need for Translational Pharmacovigilance





Clinical Research




Practice

Transition from bench to bedside Genomics and Pharmacovigilance

Warfarin - the most widely prescribed oral anticoagulant

Label advice (2007): Altered metabolism of warfarin in patients with particular variants in the cytochrome P450 2C9 (*CYP2C9*) or vitamin K epoxide reductase complex subunit 1 (*VKORC1*) genes requires dose adjustment.

VKORC1 & CYP2C9 Genetic Prevalence



70% Genetic Variants Require Lower Dose Warfarin 30% Wild-type Standard Dose Warfarin

Transition from bench to bedside Genomics and Pharmacovigilance

	Abacavir drug label change introduced by the EMEA in 2008				
Abacavir – antiretroviral agent	Before initiating treatment with abacavir, screening for carriage of the HLA- B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA- B15701 allele unless so other thereas the scheen is surgicable in these patients.				
Patients who carry the HLA-B*5701					
allele are at high risk for experiencing a	B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing				
hypersensitivity reaction to abacavir.	Abacavid and lebel charge introduced by the EDA in 2008				
Prior to initiating therapy with abacavir,					
screening for the HLA-B*5701 allele is	Patients who carry the HLA-B*5 D1 afele are at high tisk for experiencing hypersensitivity reaction to abacavir. Prior to initiating therapy with abacavir				
recommended; this approach has been	screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also				
found to decrease the risk of	recommended prior to reinitiation of abacavir in patients of unknown HLA- B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative				
hypersensitivity reaction.	patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive nationts				

Transition from bench to bedside Genomics and Pharmacovigilance

Carbamazepine – antiepileptic

Testing for the **HLA-b*1502 allele in**

Asians is recommended to identify

individuals who are at increased risk for

Stevens–Johnson syndrome or toxic

epidermal necrolysis after taking

carbamazepine

PV Challenges in India

Spontaneous ADR Reporting

- Long term safety data can only be captured through pharmacovigilance
 - SAEs
 - SUSARs
- Safety data obtained through clinical trials are from "Controlled situation"

Process in Pharmacovigilance

- Collect and record of AEs / ADRs
- Causality assessment and analysis of ADRs
- Collate and code in database
- Compute risk-benefit and suggest regulatory action
- Communicate for safe use of drugs among stakeholders



Process in Pharmacovigilance

- Collect and record of AEs / ADRs
- Causality assessment and analysis of ADRs
- Collate and code in database
- Compute risk-benefit and suggest regulatory action
- Communicate for safe use of drugs among stakeholders



Adverse Event reporting Form

ADVICE ABOUT REPORTING

- · Report adverse experiences with medications
- Report serious adverse reactions. A reaction is serious when the patient outcome is:
 - death
 - life-threatening (real risk of dying)
 - hospitalization (initial or prolonged)
 - · disability (significant, persistent or permanent
 - congenital anomaly
 - required intervention to prevent permanent impairment or damage

Report even if:

- You're not certain the product caused adverse reaction
- you don't have all the details, however, point nos. 1, 5, 7, 8, 11, 15, 16 & 18 (see reverse) are essentially required.

Who can report:

 Any health care professional (Doctors including Dentists, Nurses and Pharmacists)

Where to report:

- Please return the completed form to the nearest Adverse drug reaction Monitoring Centre (AMC) or to National Coordinating Centre
- A list of nationwide AMCs is available at: http://odsco.nic.in/pharmacovigilance.htm

What happens to the submitted information:

- Information provided in this form is handled in strict confidence. The causality assessment is carried out at Adverse Drug Reaction Monitoring Centres (AMCs) by using WHO-UMC scale. The analyzed forms are torwarded to the National Coordinating Centre through the ADR database. Finally the data is analyzed and forwarded to the Global Pharmacovigilance Database managed by WHO Uppsala Monitoring Center in Swedan.
- The reports are periodically reviewed by the National Coordinating Centre (PvPI). The information generated on the basis of these reports helps in continuous assessment of the benefit-risk ratio of medicines.
- The information is submitted to the Steering Committee of P-VI constituted by the Ministry of Health and Family Welfare. The Committee is entrusted with the responsibility to review the data and suggest any interventions that may be required.

Suspected Adverse Drug Reaction Reporting Form

For VOLUNTARY reporting of suspected adverse drug reactions by health care professionals



Central Drugs Standard Control Organization Discore General of Health Services. Ministry of Health & Fornity Welfare, Gevernment of India, PDA Shavan, ITO, Katle Roed, New Dath - 170002 www.cdaco.rtic.in

Pharmacovigilance Programme of India ^{for} Assuring Drug Safety

Pharmacovigilance Programme of India (PvPI) National Coordinating Centre, Department of Pharmacology, All India Institute of Medical Sciences Ansari Nagar, New Dehi – 110029 Phone no: 011-26503282, 26588422 Fax no: 011- 11-20588003, 26588641

Email: pvpi.ncc@gmail.com

Confidentiality: The patient's identity is held in skict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter's identity in response to a request from the public. Submission of a report does not constitute an admission has medical personnel or manufacturer or the product caused or contributed to the reaction.

SUSPECTED ADVERSE DRUG REACTION REPORTING FORM

For VOLUNTARY reporting of Adverse Drug Reactions by healthcare professionals

CDSCO										AMC/ NCC Use only				
Central Drugs Standard Control Organization										ANC Re	part no.			
Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India,														
			a Road, New I							Workhy	ide Unique	I ND.		
www.cdeco.nic.in										I				
		_												
A. Patient information								12. Relevant tests/ laboratory data with dates						
1. Patient	initials.	2. Age at th		3.8ex DM DF										
		EVEN OF	date of birth	I —		_								
				4.Weight		Kan								
D. Europeined Adverse Describes														
B. Suspected Adverse Reaction 5. Date of reaction started (ddnm/yy):								13. Other rele	want histor	x indiading	pro-existin	o medical conditions		
 Date of reaction stands (dominyy); Date of recovery (ddimmiyy); 								 Other relevant history, including pre-existing medical conditions (e.g., allergies, race, pregnancy, smoking, alcohol use, hepatic/ 						
		or problem				_	1	renal dyst	unction, etc	10				
		or process												
								14. Sericusness of the reaction						
								Death (dd			D Con	genital anomaly		
								Life thread				uired intervention		
								Hospitaliz				revent permanent		
								or prolong Disability	60			airment/ damage or (specify)		
								-				- oberell		
								 Outcomer Patal 	15. Outcomes					
								Patal Pecovering Unknown Continuing Pecovered Other (specify)						
C. Sun	pected n	nedicatio	n (s)			_								
8 No.	ne (brand								Therapy	clates (if up	Known.	Reason for Use		
	or generic	tarer (if	1 Lot May	ixp. Date	Dose		ute	Frequency	requency plu)	er.		
**** B	amej	known)	(Fknown)			LID.	ea		Date star	e started Date stopped prescribed for				
							_							
_							_							
-							-							
iv.														
Si. No.		tion abalied No.	Unknown	peti or dosi NA		f aced	dage		tion reappoint No.	ured after Unknown	NA.	in if reintraduced, dose		
As per C	165	110	CONTONE	10	POREL	1000	aose	105	780	OR BOROWIN	364	1114110303.080, 0068		
	-	+	-	-	-									
-														
iw -														
			kets including					D. Repor	ter (see i	confiden	tiality se	ection in first page)		
	al remedic reaction)	is with the	apy dates (o	clude thos	e used	10		16. Name an	d Professio	eal Addres	66			
1.000	-sacard (
								Pin code:E-mail:						
								Tel. No. (with STD Code):						
								Occupation Signature:						
								17. Causality Assessment: 18. Date of this report (dd/mm/yy)						
								10. Date of this report (domining))						

AE/ ADR reports: Sources

• Spontaneous Reporting Systems

- From Health care Professionals (voluntary)-high incidence of under reporting

- Published scientific literature: Pubmed, Scopus etc.
- Periodic Safety Update Report (PSUR)

Other methods for collecting AEs/ ADRs

ACTIVE SURVEILLANCE

- **Site surveillance** (hospitals, pharmacies, nursing homes etc.)
- Focused ADR monitoring of drugs
- Prescription event monitoring
- Disease registries from Public health Programme

COMPARATIVE OBSERVATIONAL STUDIES

- Cross sectional survey
- Case control study
- Cohort studies
- Large safety trial
- Drug utilization study

Process in Pharmacovigilance

- Collect and record of AEs / ADRs
- Causality assessment and analysis of ADRs
- Collate and code in database
- Compute risk-benefit and suggest regulatory action
- Communicate for safe use of drugs among stakeholders



Causality Assessment (CA) and Analysis of AEs/ADRs

Assessment and Analysis

- Quality check for completeness of the reported case
- Validity of the case
- Perform case follow-up (if necessary)
- Causality assessment

Causality Assessment (CA) and Analysis of ADRs

Quality and Validity

- Check for the Mandatory fields
- Valid report should have
 - Patient information
 - Date of Reaction
 - Adverse event
 - Suspected medication
 - Reporter (Source)

Causality Assessment (CA) and Analysis of ADRs

CA Scale

- Bayesian system
- European ABO system
- Jones scale
- Karch & Lasagna scale
- Kramer's scale
- Naranjo's scale
- Spanish quantitative imputation scale
- WHO-UMC probability scale


Process in Pharmacovigilance

- Collect and record of AEs / ADRs
- Causality assessment and analysis of ADRs
- Collate and code in database
- Compute risk-benefit and suggest for regulatory action
- Communicate for safe use of drugs among stakeholders



Collate and Code in database

• ADR reports entry in Database




- Coding of events and drugs
 - Events
 - WHO-ART
 - MedDRA
 - Drugs
 - WHO-Drug dictionary

Process in Pharmacovigilance

- Collect and record of AEs / ADRs
- Causality assessment and analysis of ADRs
- Collate and code in database
- Compute risk-benefit and suggest regulatory action
- Communicate for safe use of drugs among stakeholders



Compute risk-benefit ratio



One man's meat is another man's poison !!!

Compute risk-benefit ratio

Signal

Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously.

Drug Safety 1994

Suggest Regulatory Action

 Suggest warnings and alerts for regulatory agency



Widening Scope in Pharmacovigilance

ADR reports of new drugs



- Medication errors and irrational use of medicines
- Herbal, traditional and complimentary medicines
- Substandard medicines and counterfeit medicines
- Blood products, biologicals, medical devices and vaccines

Drugs recently banned in India


- Rosiglitazone
- Sibutramine
- Rimonabant
- Nimesulide (Under 12 years)
- Cisapride
- Phenylpropanolamine
- Gatifloxacin and
- Tegaserod

Process in Pharmacovigilance

- Collect and record of AEs / ADRs
- Causality assessment and analysis of ADRs
- Collate and code in database
- Compute risk-benefit and suggest regulatory action
- Communicate for safe use of drugs among stakeholders



Communication among Stakeholders



Lag Period between Signal Detection & Regulatory Action





BREAKING NEWS



Quality control of PV data

- Quality of Individual Case Safety Reports
- Incomplete/ missing information
- Inconsistencies in reporting
 - Coding of reaction terminologies
 - WHO-ART/ MedDRA
 - India???

use of local terms like:

"mata" for ?chicken pox ?measles

"mirgi" for ?epilepsy ?hysteria

Periodic Quality Assessment


Reasons for underreporting

- Considered as additional burden
 - Little obvious or immediate return
 - Time consuming

• To avoid scrutiny of professional competence

• Insufficient awareness/ training

Improving AE Reporting



Good Reporting Practice

Interaction with Physicians & Paramedics

- Developing one-to-one rapport
- Two way communication



Hybrid AE Reporting Model

Harmonization of PSUR/ PMS

PvPI Centre & Associated Hospitals

-Active / Spontaneous Reporting Reminders: Telephone/ SMS/ Drop box

PV Data from Pharma Industry Corporate Hospitals/ Nursing homes/ Rural Health Setup

> Apollo/ Fortis/ Medanta/ CARE...

Hybrid AE Reporting Model

PvPI Centre & Associated Hospitals Reminders: Telephone/ SMS/ Drop box


Harmonization of PSUR/ PMS

How to Integrate different modes - Central Database Pharma Industry

Setup

Apollo/ Fortis/ Medanta/ CARE...

Reaching rural India for PV



Education in PV

- Catch them young philosophy
 UG Curriculum (MBBS, Pharmacy, Nursing)
- Continuing education for postgraduates

• CMEs for practicing healthcare professionals

• Role of M.C.I, P.C.I., I.N.C.

PV Education...

- The Good
 - Help sustain reporting culture
- The Bad



- Mushrooming of PV course providers
- The Ugly
 - Training by untrained professional
 - Lack of standard training

Media management & PV in India

- Publicity driven reporting
 - Over reporting
 - Misreporting

• Due/ Undue public scare



Where do we stand?

Challenges for India

 Safety data from developed countries may not be directly applicable

- Difference in genotype and phenotype of pts
- Social and economic conditions are different
- Concomitant illness and medications

Clioquinol induced SMON in Indians

- 10,000 cases of SMON in Japan over 15-years
- India:
 - A retrospective study of 5,168 records (1967-71)
 - ✓ 2 cases compatible with SMON
 - A prospective study (1972-77)
 - ✓ 7 cases of SMON only One definite
- "Drug <u>not</u> banned for adults"

(Wadia NH. Some observations on SMON from Bombay. J Neurol Neurosurg Psychiatry. 1977 ;40(3):268-75.)

Drugs banned elsewhere.... available in India

Nimesulide

(Not for children under 12 years of age)

- Phenylbutazone
- Metamizole
- Quiniodochlor

- Hepatic failure
- Blood dyscrasias
- Agranulocytosis
- Subacute myelo-optic neuropathy (SMON)

Drugs banned in India

- Cisapride
- Gatifloxacin
- Rosiglitazone
- Sibutramine
- Tegaserod
- Rimonabant
- PPA

- QT prolongation
- Hypo/hyperglycemia
- Adverse Cardiac events
- Adverse Cardiac events
- Heart Attack, stroke
- Suicidal Ideation
- Hemorrhagic stroke

Pharmacovigilance in India

1986

ADR monitoring system for India proposed (12 regional centres

1997

India joined WHO-ADR monitoring programme (3 centres: AIIMS, KEM, JLN)

2004 – 2008

National Pharmacovigilance prog. (2 Zonal, 5 Regional, 24 Peripheral Centres)


2010...

Pharmacovigilance Programme of India (PVPI)

Pharmacovigilance Programme of India (PVPI) was launched in July 2010.

Goal

To ensure that the benefits of use of medicine outweighs the risks and thus safeguard the health of the Indian population




Centres in First wave of PvPI: 12 + 10 = 22

Current no. of centres in PvPI: 22 + 38 = 60


Pharmacovigilance activities done under National Coordinating Centre at AIIMS

1201 ADR reports entered in Vigiflow by NCC



7329 ADR reports entered in Vigiflow by

ADR Monitoring Centres



PHARMACOVIGILANCE OF ANTIMALARIAL MEDICINES IN INDIA

with special emphasis on Artemisinin Combination Therapy (ACT)

National Institute of Melaria Research, National Vector Borne Disea as Control Programme & Department of Pharmacology, All India Institute of Medical Sciences, New De Ihi

IMPORTANT INSTRUCTIONS

- The completely filled form should be sent to:
- Coordin ator, National Pharmacovigilance Programme, Departmento (Pharmacology, Roomnio, 4012, 4⁴ floor, Teaching Block, Al India Institute of Medical Sciences, Ansari Nagar, New Dehi – 110029
- Please note that Artemisinin combination therapy is not recommended in pregnancy in India.
- The adverse even treporting formshould be filled in a clear and legible handwriting.
- The form has beep a fat.
- Part A (treatment visit) of the form should be filled on the day when the treatment of a malaris patient is started.
 - Please mention all the malaria reliated symptoms along with their duration.
 - Specifically ask the patient for any other clinical events developing in 7 days before the visit which are notrei alled to malaria and mention in the relevant section. E.g. Measles, and epain, to ralitie atc.
 - Pre-existing medical conditions should include a history of conditions like diabetes, hypertension, HIV, TB, I weekidne ydi sease, allergies, alcohol, tobacco use.
 - A the time of his visit he patient must be asked to return between 7 15 days and should be given a til kee up appointment (birfilling up PartB).
- Part B (follow up visit) of he form should be filled between 7 15 days for partA and not with the regular 3 day follow up.
 - If the type of to low up is other than the visit to centre/home, mention in the space provided. It could be a telephonic to low up or all ost to to low up (the patient could not be contaided after first visit)
 - Ask the patient for all the medicines that heathe consumed while on anti-melanial drugs for possible drug-drug interactions.
 - a Details of workening of an existing problem or a new event should in dude any adverse reaction that the patient develop ed after the tast visit. Any such event should be described in detail along with the date of stat, date of stopping, name of the medicine which in your view is a sponsible for the event and the outcome of this adverse event.
- All the medicine names should include pharmecological as well asbiand name of the drug.
- The report should be sentimmed also if the outcome of an a dware event is: dea bill fe-threatening/ persistent incapacity or deability/ caused or prolonged hospitalization.
- Your identity will remain confidential and this information will not be used for any medico-legial purpose.
- Submission of this form does not imply that the medidine or reporting person is responsible for the adverse event.
- This information will be analyzed and will contribute to promoting safe use of antimaterials.
- For any que ly regarding filing up the trims/suggestions contact

Principal investigators

- Dr. Neena Valecha, MD, Scientistif, NMR, n eenavalecha@gmail.com,011-28307432
- 2. Dr. AnupAnvikar, MD, Scientist D, NIMR, anvikan@edifmail.com, 011 25307122
- Pinf, YK, Gupta, MD, He ad, Dept. of Pharmacology, AIMS, ykykgupta@gmail.com, 011-28553282

Budy Coord Inster

Dr. Pooja Gupta, MD, Senior Resident, Department of Pharmacology, AIMS, drgupta pooja@gmail.com, 011-20200884

PHARMACOVIGILANCE OF ANTIMALARIAL MEDICINES IN INDIA

With special emphasis on Artemisinin Combination Therapy (ACT)






National Institute of Malaria Research National Vector Bome Disease Control Programme Department of Pharmacology Al India Institute of Medical Sciences, New Delhi

> Website: http://www.mrcindla.org Email:malaria.safety.india@gmail.com


The form may also be photocopied and used.







Data Flow



Current Status

S.no.	City/ State	No of Forms	Total no. of ADR Reports
1	Gujarat	616	
2	Karnataka	207	For the period
3	Mumbai	4	Nov '09 -May' 11
4	Manipur	6	1200 ADRs received at AIIMS
5	Nagaland	16	
6	Meghalaya	10	Total Adverse Events: 42
7	Mizoram	51	
8	Orissa	12	
9	Chattisgarh	5	
10	Madhya Pradesh	30	

Strategies adopted to boost reporting

- Monthly telephonic follow up with District Malaria Officers
- Personalized thank you emails to reporting Medical Officers
- Interesting study material related to vector borne diseases sent by email

Adverse Event Following Immunization (AEFI)

 A medical incident that takes place after an immunization which causes concern and is believed to be caused by immunization (WHO)

Adverse Events to HPV Vaccine

- HPV vaccine demonstrated to be safe in the premarketing clinical trials
- 7 deaths in India in one post-marketing study
 - Clear causality with the vaccine was not established
- Lessons learned in the process
 - Public distrust can adversely affect any healthcare programme
 - Timely addressing such concerns is crucial

Measles vaccination drives


- Clusters of deaths
 reported in India
 - Tamil Nadu, Assam,
 UP
 - Mostly due to programme error
 - Quality of the vaccines ??







Proposed System for AEFI in India



Integrated Medicine Management System (IMMS at AIIMS)

- To promote standard and generic drugs through the government hospitals
- Model being prepared by the AIIMS

 Link with pharmacovigilance (Alerts)
- Major anticipated benefits
 - Monitor quality of drugs,
 - Minimize ADR, medication errors,
 - Prescription tracking



Partnering for Progress





Thank you